Drugs / Favezelimab
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02720068 | May 2016 → Mar 2024 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06395090 | Jan 2025 → Jun 2029 | metastatic neoplasm | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04305054 | Jul 2020 → May 2026 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT03598608 | Oct 2018 → Jan 2026 | classic Hodgkin lymphoma, large B-cell lymphoma, non-Hodgkin lymphoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT03516981 | Oct 2018 → Jun 2025 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 2 | NCT02625961 | Feb 2016 → Nov 2025 | urinary bladder cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT05600309 | Jun 2022 → Aug 2024 | colorectal cancer | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT03486873 | Aug 2018 → Aug 2043 expected | cancer, hematopoietic and lymphoid cell neoplasm | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-25 | Merck Sharp & Dohme LLC | Results Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer merck.com ↗
At the final pre-specified analysis, the favezelimab and pembrolizumab fixed-dose combination did not demonstrate an improvement in OS compared to standard of care (regorafenib or TAS-102 [trifluridine and tipiracil hydrochloride]). |
All press releases naming this drug 2 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | favezelimab | “Participants receive MK-4280A (800mg favezelimab + 200mg pembrolizumab) as IV infusion every 3 weeks (Q3W) and may continue study therapy until study treatment completion or...” NCT03486873 ↗ |
| Known as | Favezelimab/pembrolizumab coformulation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02625961 ↗ |
| Action | Inhibit | “anti-LAG-3 favezelimab” PMID 37429923 ↗ Jul 2023 |
| Route | Intravenous | “receive favezelimab/pembrolizumab (coformulation of 800mg favezelimab and 200 mg pembrolizumab) via IV infusion” NCT02625961 ↗ |
| Target | LAG3 | “LAG-3 antibody favezelimab” PMID 36493599 ↗ Dec 2022 |